静脉注射三磷酸腺苷和磷酸肌酸联合氟西汀治疗重性抑郁障碍:随机双盲安慰剂对照预试验方案
重性抑郁障碍(MDD)常用抗抑郁药需4-6周起效,且仅50-75%患者应答。基于ATP和PCr在抑郁动物模型中快速起效的发现,本研究为首个临床尝试,采用单中心随机双盲安慰剂对照预试验,计划纳入42例患者随机分三组,前2周静脉给予ATP或PCr或生理盐水每日两次联合口服氟西汀20 mg/日,后4周氟西汀单药治疗,第10周随访评估可行性、安全性和疗效趋势。
要点
- 首个静脉ATP/PCr联合氟西汀治疗MDD的临床预试验,采用随机双盲安慰剂对照设计。
- 计划纳入42例患者,前2周静脉给药联合口服氟西汀20 mg/日,后4周氟西汀单药,第10周随访。
- 主要评估可行性结局(入组率、依从性、脱落率等)及安全性,并探索疗效趋势。
核心结论
- 本研究为首次临床尝试静脉注射ATP和PCr联合口服氟西汀治疗MDD,旨在评估可行性、安全性及疗效趋势,为后续完整试验设计和样本量计算提供依据。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照预试验,计划纳入42例MDD患者随机分为三组。
- 前2周静脉给予ATP或PCr或生理盐水每日两次,联合口服氟西汀20 mg/日;后4周氟西汀单药治疗;第10周完成随访评估。
主要发现
- 原文未报告结果,本方案主要评估可行性结局(患者合格百分比、用药意向、参与意愿、药物依从性、预定评估完成率、保留率、脱落率等)及安全性指标。
- 疗效趋势通过汉密尔顿抑郁量表减分率、临床总体印象量表平均变化和患者健康问卷-9项评估。
关键数值与推荐
- 氟西汀口服剂量为20 mg/日;静脉ATP或PCr或生理盐水每日两次,持续2周。
- 可行性结局包括患者合格百分比、用药意向、参与意愿、药物依从性、预定评估完成率、保留率、脱落率等。
- 安全性评估记录体格检查、副作用评定量表、不良事件、血液检查、脑电图和心电图结果。
临床怎么用
- 静脉ATP/PCr联合氟西汀的增补治疗需住院前2周以监测安全性,住院可能影响招募、参与、脱落和疗效等。
- 本预试验的可行性、安全性和疗效趋势结果将用于设计完整试验和计算样本量。
局限性
- 为单中心预试验,样本量小(42例),主要评估可行性而非确证疗效。
- 前2周需住院可能影响招募、参与、脱落、疗效和结果等。
- 原文未报告研究结果,无法得出疗效或安全性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major depressive disorder (MDD) is a common psychiatric disorder. With systematic antidepressant treatment, 50-75% of patients have a treatment response but require 4-6 weeks to have their symptoms alleviated. Therefore, researchers anticipate the development of novel fast-acting antidepressants. Previous studies have revealed that the decrease of bio-energetic metabolism may contribute to the occurrence of depression, while our team has found adenosine triphosphate (ATP) and phosphocreatine (PCr) to be fast-acting antidepressants in the depressed-animal model. ATP and PCr have already been widely prescribed clinically as energy supplements for cells. This will be the first clinical attempt of the intravenous administration of ATP and PCr combined with orally administered fluoxetine in MDD. METHODS: This is a single-center, randomized, double-blind, placebo-controlled pilot study. A total of 42 patients will be divided randomly into three groups. Patients will receive an intravenous administration of ATP or PCr or saline twice daily combined with orally administered fluoxetine (20 mg/day) for the first 2 weeks and fluoxetine monotherapy for the following 4 weeks. Follow-up assessment will be completed at week 10. Feasibility outcomes will include percentages of patient eligibility, intention to use medication, willingness to participate, drug adherence, completion of the scheduled assessment, retention, drop-out, etc. Physical examination results, Side Effect Rating Scale, adverse events, results from blood tests, electroencephalogram, and electrocardiograph will be recorded for safety evaluation of the augmentation therapy. The trends of efficacy will be evaluated by the reduction rate of the Hamilton Depression Rating Scale, the mean change of the Clinical Global Impression Scale, and the Patients Health Questionaire-9 items. DISCUSSION: In our study, ATP and PCr will be given by intravenous infusion. Thus patients will be hospitalized for the initial 2 weeks for safety concern. Hospitalization will be an impact factor for the recruitment, participation, drop-out, efficacy, results, etc. The evaluation of our feasibility outcomes, study setting, safety of augmentation therapy and possible efficacy trends among groups, will facilitate a full-scale trial design and sample size calculation. TRIAL REGISTRATION: NCT03138681 . Registered on 3 May 2017. First patient: 4 May 2017.
引用
- Chen Y, Cao X, Zang W, et al. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study. Trials. 2019. PMID: 30626424. doi:10.1186/s13063-018-3115-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。